Cagrilintide
- Evidence
- Moderate research
- Class
- Long-acting amylin analog
Cagrilintide belongs to the Long-acting amylin analog class. This library groups it under digestive & weight. Its source category is In clinical trials.
At a glance
| Compound class | Long-acting amylin analog |
|---|---|
| Body system | Digestive & weight |
| Use or research focus | Obesity |
| Regulatory status | Investigational (Phase 3) |
| Source evidence rating | Moderate research |
How does Cagrilintide work?
Amylin receptor agonist; satiety.
The source catalog maps this mechanism to Brain / CNS, Whole-body / Metabolic. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog describes an intermediate evidence base. Early clinical findings may leave questions about effectiveness, dose, interactions, and long-term safety. Read the individual studies before drawing conclusions about a specific use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
A compound being studied in a clinical trial is not necessarily approved or effective. Trial participants follow a study protocol with eligibility criteria and monitoring. Results from one population or formulation may not apply to another.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Cagrilintide?
Cagrilintide belongs to the Long-acting amylin analog class. This library groups it under digestive & weight. Its source category is In clinical trials. Its recorded use or research focus is: Obesity.
Is Cagrilintide FDA-approved?
The catalog records: Investigational (Phase 3). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog describes an intermediate evidence base. Early clinical findings may leave questions about effectiveness, dose, interactions, and long-term safety. Read the individual studies before drawing conclusions about a specific use.
Where can I read the research?
The Citations tab contains 15 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for digestive & weight
Factual catalog fields and citation links are adapted from Superpower’s Cagrilintide guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Cagrilintide in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01calcitonin receptorsdoi.org
- 02incretin systemncbi.nlm.nih.gov
- 03combinationdoi.org
- 04started a standalone Phase 3 trialclinicaltrials.gov
- 05cannot be used in compounding under federal lawfda.gov
- 06FDA-approved as an adjunct to mealtime insulindailymed.nlm.nih.gov
- 07up to 10.8% weight losspubmed.ncbi.nlm.nih.gov
- 0820.4% mean weight loss over 68 weekspubmed.ncbi.nlm.nih.gov
- 0914.9% shown by semaglutide 2.4 mgpubmed.ncbi.nlm.nih.gov
- 1020.9% shown by tirzepatide 15 mgpubmed.ncbi.nlm.nih.gov
- 1117.1% weight loss at 20 weekspubmed.ncbi.nlm.nih.gov
- 12amycretin, a single-molecule GLP-1 and amylin receptor agonistpubmed.ncbi.nlm.nih.gov
- 13no clinically relevant QTcF prolongationpubmed.ncbi.nlm.nih.gov
- 14selective amylin receptor agonistpubmed.ncbi.nlm.nih.gov
- 15submitted to the FDA for reviewsec.gov